Open Access

Metabolic reprogramming in cancer cells: glycolysis, glutaminolysis, and Bcl-2 proteins as novel therapeutic targets for cancer

  • Chunxia Li1Email author,
  • Guifeng Zhang2,
  • Lei Zhao1,
  • Zhijun Ma1 and
  • Hongbing Chen3
World Journal of Surgical Oncology201614:15

https://doi.org/10.1186/s12957-016-0769-9

Received: 30 November 2015

Accepted: 11 January 2016

Published: 20 January 2016

Abstract

Nearly a century ago, Otto Warburg made the ground-breaking observation that cancer cells, unlike normal cells, prefer a seemingly inefficient mechanism of glucose metabolism: aerobic glycolysis, a phenomenon now referred to as the Warburg effect. The finding that rapidly proliferating cancer cells favors incomplete metabolism of glucose, producing large amounts of lactate as opposed to synthesizing ATP to sustain cell growth, has confounded scientists for years. Further investigation into the metabolic phenotype of cancer has expanded our understanding of this puzzling conundrum, and has opened new avenues for the development of anti-cancer therapies. Enhanced glycolytic flux is now known to allow for increased synthesis of intermediates for sustaining anabolic pathways critical for cancer cell growth. Alongside the increase in glycolysis, cancer cells transform their mitochondria into synthesis machines supported by augmented glutaminolysis, supplying lipid production, amino acid synthesis, and the pentose phosphate pathways. Inhibition of several of the key enzymes involved in these pathways has been demonstrated to effectively obstruct cancer cell growth and multiplication, sensitizing them to apoptosis. The modulation of various regulatory proteins involved in metabolic processes is central to cancerous reprogramming of metabolism. The finding that members of one of the major protein families involved in cell death regulation also aberrantly regulated in cancers, the Bcl-2 family of proteins, are also critical mediators of metabolic pathways, provides strong evidence for the importance of the metabolic shift to cancer cell survival. Targeting the anti-apoptotic members of the Bcl-2 family of proteins is proving to be a successful way to selectively target cancer cells and induce apoptosis. Further understanding of how cancer cells modify metabolic regulation to increase channeling of substrates into biosynthesis will allow for the discovery of novel drug targets to treat cancer. In the present review, we focused on the recent developments in therapeutic targeting of different steps in glycolysis, glutaminolysis and on the metabolic regulatory role of Bcl-2 family proteins.

Background

In 1924, Otto Warburg made the landmark discovery that, unlike most somatic cells that rely heavily upon oxidative phosphorylation for efficient and adequate synthesis of ATP to sustain their functions, cancer cells predominantly depend on aerobic glycolysis and produce large amounts of lactate [1]. Why cancer cells would favor a less efficient mechanism for energy production has long puzzled researchers—a rapidly proliferating cell would be expected to have extensive energy demands. Initially, it was surmised that this metabolic switch resulted from damage to mitochondrial function. For nearly a century since the first observations of the “Warburg effect”, increasing evidence has led to the realization that the metabolic switch in cancer cells is in fact the result of a highly complex, insidious process of reprogramming achieving a metabolic state ideal for the proliferation and sustenance of cancer cells. Historically, mutations in genes regulating proliferation and growth signaling were thought to be the primary triggers of carcinogenesis, changes in metabolism seen as the cells simply “keeping up” with the demands of higher multiplication rates. However, the finding that many of these oncogenes moonlight as critical regulators of metabolism and that their dysregulation contributes to altered metabolic phenotypes that favor growth, has called for a re-evaluation of metabolic reprogramming as an emerging hallmark of cancer [2, 3]. A significant shift in our understanding of metabolic state as a central transformative force in cancer cell development was sparked by observation that changes in metabolism can modulate a cell’s ability to differentiate [4, 5], diverging from the paradigm that metabolic reprogramming is an adaptation to mutations in order to maintain biosynthesis and suggesting that an altered metabolic state can itself enhance growth and survival. Continued research in this area may lead to the development of powerful therapeutics that can selectively target cancer cells by obstructing their metabolic evolution. The reprogrammed metabolism of cancer cells is instrumental in achieving other well-described hallmarks of cancer such as limitless proliferation and escape from apoptosis. Many of the metabolites (e.g., (R)-2-hydroxybutyrate, lactate, etc.) that are specifically elevated in cancer cells promote not only their proliferation and survival but also prevent their apoptosis, by either activating the anti-apoptotic Bcl-2 family proteins or increasing their expression.

In this review, we addressed the recent developments in our understanding on the derangements in cancer cell glycolysis and glutaminolysis and on the role of Bcl-2 family proteins including Mcl-1, NOXA, Bad, etc., in the regulation of reprogrammed metabolism in cancer cells. We highlighted the various suggested novel anti-cancer therapeutic targets in these metabolic pathways.

The fates of glucose in cancer cell metabolism

When completely oxidized, 1 glucose can provide up to 36 adenosine triphosphate (ATP) molecules, compared to a meager 2 ATPs per glucose via conversion to lactate through glycolysis [6]. To reconcile the befuddling discovery that cancer cells sustain rapid proliferative rates using the comparatively inefficient process of aerobic glycolysis, Warburg hypothesized that cancer cells may have defective mitochondria incapable of maintaining oxidative respiration [7]. However, it has been demonstrated that cancer cells do not necessarily exhibit compromised mitochondrial function [8, 9], suggesting that another mechanism underlies this metabolic phenotype. Aerobic glycolysis is indeed sufficient to fuel rapid proliferation, as seen in the case of many unicellular organisms such as yeast [10, 11]. Cancer cells favoring glycolysis maintain energy charge, as determined by the ratio of ATP:ADP and NAD(P)H:NAD(P)+ (NAD is nicotinamide adenine dinucleotide; NADP is nicotinamide adenine dinucleotide phosphate), suggesting that energy depletion does not result as a consequence of this metabolic shift [12, 13]. This could be due to the fact that cancer cells do not experience substrate scarcity, and are continually supplied with glucose and other nutrients from the blood. Additionally, normal cells tightly regulate energy charge and ATP synthesis to prevent uncontrolled proliferation even in the presence of abundant resources (Fig. 1). For example, increases in ATP will negatively feedback on the glycolytic pathway by inhibiting phosphofructokinase (PFK) and pyruvate kinase (PK), decreasing the conversion of glucose to pyruvate and lactate [14, 15]. When ATP is depleted, increases in AMP will activate AMPK, leading to the inhibition of anabolic processes such as protein synthesis and triggering catabolism, such as fatty acid oxidation, to replenish ATP [16]. Precise detection of cellular energy state allows for fine-tuned regulation of anabolic and catabolic pathways in the cell—interestingly, many cancer cell types show mutations in the upstream AMPK kinase LKB1, which is required for phosphorylation and activation of AMPK [17]. LKB1 is considered to be a tumor suppressor, and the loss of its function may contribute to carcinogenesis by eliminating the AMPK energy sensor and dissociating the balance between energy state and biosynthesis [18, 19]. It has been demonstrated that LKB1-deficient cancers are susceptible to treatment with the biguanide phenformin, phenformin selectively inducing apoptosis in these cancer cells as opposed to cancer cell types harboring other mutations [20]. These findings suggest that there is potential for the use of phenformin, and perhaps related compounds, in the treatment of those cancers with LKB1 defects. Activation of AMPK may also prove to be a promising target for the development of novel therapeutics against cancer. Cell culture studies have shown that activation of AMPK in cancer cells sensitizes them to chemotherapeutic agents currently used in patients [21, 22]. AMPK activators could be developed into powerful therapeutics that could be used in combination with other drugs to more effectively treat cancer (Fig. 1).
Fig. 1

Reprogramming of the glycolytic pathway in cancer cells. Cancer cells rely on increased glycolytic flux, increasing glucose uptake, and producing large amounts of lactate. The expression of the PKM2 isoform allows for flexibility in that the dimeric form will exhibit decreased activity, promoting accumulation of glycolytic intermediates that can be shunted into the pentose phosphate pathway and nucleotide synthesis. Decreased oxidative phosphorylation in normal cells would lead to decreased energy charge and increased AMP, activating AMPK. Cancer cells often harbor mutations in the upstream AMPK kinase LKB1, without whose phosphorylation activity, AMPK cannot be activated and therefore cannot inhibit anabolic pathways such as nucleotide synthesis

It has also been found that many cancer cell types preferentially express an isoform of PK, PKM2. Unlike other isoforms of this enzyme that are consistently in a tetrameric state and are largely regulated by allosteric inhibition by ATP and activation by PEP and fructose 1,6-bisphosphate, PKM2 can exist in either a highly active tetrameric state or a less active dimeric state. The PKM2 isoform is expressed in fetal tissues, but is eventually replaced with other isoforms later in development [23]. PKM2 offers tumor cells the advantage of increased metabolic flexibility—this enzyme is chiefly retained in its dimeric state in cancer cells, allowing glycolytic intermediates to build-up and channel into anabolic pathways such as phospholipid, nucleotide, and amino acid synthesis that can sustain cellular replication [12, 24]. If necessary, however, PKM2 can also switch to its active tetrameric form in response to modulation by fructose 1,6-bisphosphate in order to increase pyruvate synthesis and increase ATP production. Studies investigating the possibility of activating PKM2 to hamper the capacity of cancer cells to accrue crucial biosynthetic intermediates have provided evidence that the use of small-molecule PKM2 activators may indeed be effective in impeding tumor growth [25, 26].

As mentioned above, cancer cells, which conduct high levels of glycolysis, produce lactate in large amounts and this metabolite is transported out of the cell into extracellular environment. Glycolytically produced pyruvate is converted to lactate by lactate dehydrogenase (LDH), and this step is essential for the regeneration of NAD+ in the cytosol to let high rates of glycolysis prevail, which is needed for oncogenesis. There are five different LDH subtypes (LDH 1–5), which occur as homo- or hetero-tetramers of muscle-type subunits encoded by LDH-A gene and heart-type subunits encoded by LDH-B gene. Cellular levels of lactate are governed by differential expression of LDH isoforms, the lactate monocarboxylate transporter (MCT), and the oxidative capacity of cell. Many studies have shown that several types of cancer cells require LDH-A gene, which encodes LDH-5 isoenzyme, for their maintenance and proliferation [27, 28], even though the precise mechanisms by which LDH-5 promotes cancer progression is not known. LDH-5 expression by LDH-A gene is under the control of HIF-1α and is elevated under hypoxic conditions. In fact, it is well known that HIF-1α expression is elevated in many cancers and is known to offer protection to cancer cells. Expression of HIF-1α and LDH-5 are found to be correlated and associated with poor prognosis of many cancers [29]. Importance of LDH-5 as an anti-cancer target has been explored extensively, and it has been found that either suppression of LDH-5 levels by RNAi-based approaches or by pharmacological inhibition cause significantly attenuated cancer cell proliferation and apoptosis [27, 30]. Myc oncogene, which is activated in many cancers, is known to regulate the transcription of several cellular proliferation-related genes and microRNAs and also enhances the expression of LDH-A [31]. Many cancer cells convert significant proportion of glucose to lactate, thus producing an acidic microenvironment surrounding the cancerous tissue. This acidification of the extracellular microenvironment is known to be advantageous to the tumors, by favoring invasion and suppression of cytotoxic T lymphocytes. Transport of lactate along with a proton, out of the cell is facilitated by MCT and there are many isoforms of MCT. It has been shown that inhibition of MCT by pharmacological agents was effective in curtailing angiogenesis and tumor progression of gliomas [32]. It has been suggested recently that MCTs, which are overexpressed in cancers act as “Trojan horses” as they can be exploited for transporting bromopyruvate, an anti-cancer agent into cancer cells to inhibit glycolysis [33]. Thus, overall, it appears that glycolysis-derived lactate and its handling by LDH and MCT in cancer cells provide growth advantage.

Glutaminolysis: the mitochondria as an anabolic apparatus

Apart from glucose, the other major substrate that contributes to energy production is glutamine [34]. Glutaminolysis is upregulated in many types of cancer, glutamine providing the crucial source of nitrogen to these rapidly proliferating cells for amino acid synthesis via glutamate production and transamination. Furthermore, instead of oxidizing glutamine completely to produce ATP, the mitochondria of cancer cells shunt glutamine into citrate for lipid production and for the production of NADPH by isocitrate dehydrogenase (IDH), and into malate which can also be converted to pyruvate by malic enzyme and produce NADPH [35]. Hence, both glucose and glutamine are utilized to replenish synthetic intermediates as opposed to being oxidized for ATP—though it may appear that this form of metabolism is inefficient, the increased production of ATP does not meet the requirements of a rapidly multiplying cell as effectively. As a result of this switch to increased glutamine dependence by the mitochondria, the diminished contribution of glucose to the tricarboxylic acid (TCA) cycle is well-compensated for by contributions from glutamine, and the mitochondria are transformed into apparatuses for the synthesis of building blocks required to sustain rapid cell division (Fig. 2). This mitochondrial reprogramming results from increased expression of the oncogenic transcription factor Myc, which increases expression of glutaminase and glutamine transporters to support increased glutaminolysis, and also augments expression of lactate dehydrogenase A (LDH-A) which allows shunting of glucose-derived pyruvate away from the mitochondria and into lactate [31, 36].
Fig. 2

Increased glutaminolysis and the role of the mitochondria in cancer cells. The mitochondria of cancer cells switch from the canonical function of oxidative phosphorylation and ATP production to synthesis of anabolic intermediates that can be utilized for lipid and amino acid synthesis. This is supported by high rates of glutaminolysis, Glutamine is converted to glutamate by glutaminase, and glutamate is then transaminated into α-ketoglutarate, which contributes to citrate and malate synthesis. Both of these metabolites can then be exported from the mitochondria, malate converted to pyruvate and then lactate to produce NADPH. Citrate can also be metabolized to α-ketoglutarate, synthesizing NADPH, or alternatively be channeled into lipid synthesis. PDH pyruvate dehydrogenase complex, MDH malate dehydrogenase, SDH succinate dehydrogenase, α-KGDH α-ketoglutarate dehydrogenase complex, CS citrate synthase, TA transaminase, GDC glutamate dehydrogenase

This glutamine “addiction” observed in cancer cells suggests that targeting any of the pathways involved in maintaining glutamine metabolism would exhaust cancer cells of a key substrate supply. Since increased NADPH production is one of the major benefits of this altered glutamine metabolism, a likely candidate for novel drug design is IDH. Furthermore, IDH activity is important to maintain redox regulation and scavenge reactive oxygen species (ROS) that may otherwise cause extensive damage and trigger apoptosis. Cancer cells with ablated expression of the mitochondrial isoform IDH2, had diminished capacity to form tumors when grafted into mice as compared with cancer cells where IDH2 expression was retained [37]. Interestingly, in many cancers such as glioma, colorectal cancer, and acute myeloid leukemia, IDH is mutated such that its activity is enhanced and it produces an “oncometabolite” called (R)-2-hydroxyglutarate from α-ketoglutarate. This mutation allows for increased flux of glutamine into lipid production, and (R)-2-hydroxyglutarate itself is thought to inhibit oxidative phosphorylation by inhibiting complexes of the electron transport chain, favoring channeling of glutamine away from oxidation and towards anabolic pathways [38, 39]. Additionally, mutated IDH was found to inhibit the expression of HNF4α, an important regulator of hepatocyte differentiation and proliferation, allowing liver progenitor cells to evade differentiation and maintain high replicative rates [40]. Targeting mutant IDH and decreasing its activity can effectively impose differentiation upon cancer cells, limiting their replicative potential and rendering them more susceptible to drugs that induce apoptosis [41]. Finally, tumors harboring IDH mutations are especially reliant on glutamine metabolism—another promising drug target is glutaminase, whose inhibition would starve cancer cells of glutamine, essentially shutting down biosynthesis [42, 43].

The dual personalities of the Bcl-2 family proteins

Some of the most groundbreaking discoveries highlighting the importance of metabolic reprogramming in cancer development were those implicating members of the Bcl-2 family of proteins as metabolic regulators. Bcl-2 family proteins have long been recognized as crucial mediators of mitochondrial apoptotic signaling, also referred to as intrinsic apoptosis [44, 45]. These proteins share close homologous domains known as Bcl-2 homology (BH) domains—several of the multi-domain members may contain 3–4 BH domains, Mcl-1, Bcl-2, and Bcl-xL being some of the anti-apoptotic proteins of this variety and Bak and Bax the pro-apoptotic. Some of these proteins also contain transmembrane domains, allowing them to directly embed into the mitochondrial and endoplasmic reticulum membranes [46]. Several pro-apoptotic single domain proteins, the BH3-only proteins, contain only the BH3 domain considered to be the minimal death domain, and play significant roles in determining the balance between pro- and anti-apoptotic signaling [47]. The specific interactions amongst different Bcl-2 proteins are what ultimately decide whether the intrinsic cell death pathway is activated. The pro-apoptotic Bak and Bax, both transmembrane proteins, can oligomerize to form pores, or mitochondrial outer membrane permeabilization (MOMP) that allows release of mitochondrial cytochrome c into the cytoplasm, triggering apoptosis [48, 49]. The anti-apoptotic Bcl-2 proteins do not form oligomers, and can complex with Bak or Bax preventing their oligomerization. Some of the BH3-only proteins will bind anti-apoptotic Bcl-2 proteins, sequester them away from Bax/Bak and in this way negate their anti-apoptotic effect. Other BH3-only proteins can interact with Bak and Bax, promoting their oligomerization [50].

Anti-apoptotic Bcl-2 family proteins such as Bcl-2, Bcl-xL, and Mcl-1 are frequently upregulated in various forms of cancer, promoting tumorigenesis and resistance to chemotherapy. In recent years, significant progress has been made in the development of a novel class of anti-cancer drugs that specifically inhibit the anti-apoptotic Bcl-2 family proteins, or act as BH3 mimetics. These drugs have a critical advantage over classical cytotoxic therapies that do not possess the same degree of specificity for cancerous cells and have many toxic side effects [5153]. The fascinating discovery that many of the Bcl-2 family proteins are also the key modulators of metabolism, and that their role as apoptotic mediators is in fact a secondary function, suggests that cells naturally link dysregulation of metabolism or the unavailability of substrates to cell death, a process that involves nutrient dependent changes in the expression and activity of pro- (PUMA, NOXA, Bad, and Bim) and anti-(Mcl-1) apoptotic proteins. It is also possible that cancer cell reprogramming involves altering Bcl-2 proteins to sustain a metabolic phenotype suitable for increased growth. The earliest confirmation of a metabolic role for Bcl-2 proteins was the finding that BH3-only protein BAD resides in a complex with glucokinase [54]. Glucokinase is crucial for detection of glucose in hepatocytes and pancreatic B cells, and due to its high Km for glucose and absence of product feedback inhibition, the glucokinase reaction is entirely substrate driven and acts as an ideal substrate sensor. BAD will activate glucokinase via direct interaction, which is promoted by phosphorylation of BAD by kinases such as Akt. When bound to glucokinase, BAD’s pro-apoptotic functions are defused. However, dephosphorylated BAD will dissociate from glucokinase, freeing it to bind with anti-apoptotic Bcl-2 or Bcl-xL and promote apoptosis. In certain types of cancers, it has been demonstrated that BAD phosphorylation is increased due to the increased activities of upstream kinases, and that inhibition of BAD phosphorylation decreases cancer cell survival [5557]. Sequestration of BAD to the glucokinase complex will not only prevent its pro-apoptotic functions, but will also promote increased glucokinase activity and glycolysis, a key metabolic shift that favors biosynthesis and proliferation. Although dephosphorylation of BAD alone is not adequate to trigger apoptosis, it shifts the balance towards cell death and uncouples the favorable metabolic signal of high glucose flux from regulation of cell survival.

Besides the modification of expression and activity of Bcl-2 family proteins, metabolic reprogramming in cancer cells ensures the supply of necessary metabolite building blocks for cell proliferation. Thus, the elevated glycolysis ensures the supply of glycolytic intermediates glycerol-3-phosphate and dihydroxyacetone phosphate, needed for the biosynthesis of phospholipids, the major constituents of cell membranes. Similarly, reprogramming of lipid metabolism ensures the synthesis of fatty acids and other lipids, needed for membranogenesis. In fact, the upregulated glutaminolysis not only supports the energy needs of the cancer cells but also provides the needed precursors for lipogenesis via citrate cycle, as mentioned above in the glutaminolysis section.

Another BH3-only member of the Bcl-2 family involved in metabolic regulation is NOXA. The cyclin-dependant kinase 5 (CDK5) will phosphorylate NOXA in the presence of high glucose. Phosphorylated NOXA localizes to the cytoplasm and is incapable of executing its pro-apoptotic functions—instead, it complexes with Mcl-1L and promotes increased glucose metabolism and augments flux through the pentose phosphate pathway, supporting nucleotide synthesis [58]. Indeed, NOXA is constitutively expressed in cancer cells, and many cancers exhibit increased CDK5 activity that is important for tumor growth and survival of thyroid and neuroendocrine cancers [59, 60]. Modification of the metabolic and apoptotic roles of Bcl-2 family proteins is one of the major mechanisms by which cancer cells achieve the metabolic shift necessary to meet the growth requirements. The effectiveness of therapeutics targeting this family of proteins suggests that drugs that can both increase cancer cell susceptibility to apoptosis and undo tumorigenic metabolic reprogramming may prove to be much more potent in treating cancer.

Conclusions

A consistent feature of tumor metabolism is increased glycolysis and glutaminolysis, both of which are used to supply the intermediates required to sustain amino acid synthesis, the pentose phosphate pathway, and lipid production. These metabolic outcomes are achieved via several mechanisms—however, strategies targeting cancer cell metabolism and inhibiting the Warburg effect are showing great promise as powerful, novel therapies to target cancer. Nearly a century after the first observations that cancer cells maintain altered metabolic features, the significance of metabolic reprogramming in carcinogenesis and its relevance to anti-cancer drug design continues to grow. Further research in this field will shed light on tumor progression, and how to most effectively “starve” cancer.

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Oncology, Yidu Central Hospital
(2)
Department of Oncology Nursing, Yidu Central Hospital
(3)
Department of Pediatrics, Yidu Central Hospital

References

  1. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519–30.PubMedPubMed CentralView ArticleGoogle Scholar
  2. Hanahan D, Weinberg R. The hallmarks of cancer. Cell. 2000;100:57–70.PubMedView ArticleGoogle Scholar
  3. Hanahan D, Weinberg R. Hallmarks of cancer: the next generation. Cell. 2011;44:646–74.View ArticleGoogle Scholar
  4. Moussaieff A, Rouleau M, Kitsberg D, Cohen M, Levy G, Barasch D, et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. Cell Metab. 2015;21:392–402.PubMedView ArticleGoogle Scholar
  5. Folmes C, Dzeja P, Nelson T, Terzic A. Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell. 2012;11:596–606.PubMedPubMed CentralView ArticleGoogle Scholar
  6. Lehninger A, Nelson D, Cox M. Principles of biochemistry. 2nd ed. New York: Worth; 1993.Google Scholar
  7. Warburg O. On respiratory impairment in cancer cells. Science. 1956;124:269–70.PubMedGoogle Scholar
  8. LeBleu V, O’Connell J, Gonzalez Herrera K, Wikman H, Pantel K, Haigis M, et al. PGC-1α mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992–1003.PubMedPubMed CentralView ArticleGoogle Scholar
  9. Salem A, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti M. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle. 2012;11:4174–80.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Slavov N, Budnik B, Schwab D, Airoldi E, van Oudenaarden A. Constant growth rate can be supported by decreasing energy flux and increasing aerobic glycolysis. Cell Rep. 2014;7:705–14.PubMedPubMed CentralView ArticleGoogle Scholar
  11. van Dijken J, Weusthuis R, Pronk J. Kinetics of growth and sugar consumption in yeasts. Antonie Van Leeuwenhoek. 1993;63:343–52.PubMedView ArticleGoogle Scholar
  12. Christofk H, Vander Heiden M, Harris M, Ramanathan A, Gerszten R, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452:230–3.PubMedView ArticleGoogle Scholar
  13. Rodríguez-Enríquez S, Gallardo-Pérez J, Avilés-Salas A, Marín-Hernández A, Carreño-Fuentes L, Maldonado-Lagunas V, et al. Energy metabolism transition in multi-cellular human tumor spheroids. J Cell Physiol. 2008;216:189–97.PubMedView ArticleGoogle Scholar
  14. Holmsen H, Storm E. The adenosine triphosphate inhibition of the pyruvate kinase reaction and its dependence on the total magnesium ion concentration. Biochem J. 1969;112:303–16.PubMedPubMed CentralView ArticleGoogle Scholar
  15. Vora S, Oskam R, Staal G. Isoenzymes of phosphofructokinase in the rat. Demonstration of the three non-identical subunits by biochemical, immunochemical and kinetic studies. Biochem J. 1985;229:333–41.PubMedPubMed CentralView ArticleGoogle Scholar
  16. Grahame Hardie D. AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J Intern Med. 2014;276:543–59.PubMedView ArticleGoogle Scholar
  17. Woods A, Johnstone S, Dickerson K, Leiper F, Fryer L, Neumann D, et al. LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol. 2003;13:2004–8.PubMedView ArticleGoogle Scholar
  18. Zhao R, Xu Z. Targeting the LKB1 tumor suppressor. Curr Drug Targets. 2014;15:32–52.PubMedPubMed CentralView ArticleGoogle Scholar
  19. Faubert B, Vincent E, Griss T, Samborska B, Izreig S, Svensson R, et al. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A. 2014;111:2554–9.PubMedPubMed CentralView ArticleGoogle Scholar
  20. Shackelford D, Abt E, Gerken L, Vasquez D, Seki A, Leblanc M, et al. LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin. Cancer Cell. 2013;23:143–58.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Ishijima N, Kanki K, Shimizu H, Shiota G. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. Cancer Sci. 2015;106(5):567–75. doi:10.1111/cas [Epub ahead of print].PubMedPubMed CentralView ArticleGoogle Scholar
  22. Wang Y, Liu W, He X, Fei Z. Hispidulin enhances the anti-tumor effects of temozolomide in glioblastoma by activating AMPK. Cell Biochem Biophys. 2015;71:701–6.PubMedView ArticleGoogle Scholar
  23. Christofk H, Vander Heiden M, Wu N, Asara J, Cantley L. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature. 2008;452:181–6.PubMedView ArticleGoogle Scholar
  24. Luo WSG. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol Metab. 2012;23:560–6.PubMedPubMed CentralView ArticleGoogle Scholar
  25. Anastasiou D, Yu Y, Israelsen W, Jiang J, Boxer M, Hong B, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol. 2012;8:839–47.PubMedPubMed CentralView ArticleGoogle Scholar
  26. Parnell K, Foulks J, Nix R, Clifford A, Bullough J, Luo B, et al. Pharmacologic activation of PKM2 slows lung tumor xenograft growth. Mol Cancer Ther. 2013;12:1453–60.PubMedView ArticleGoogle Scholar
  27. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006;9:425–34.PubMedView ArticleGoogle Scholar
  28. Shim H, Dolde C, Lewis BC, Wu CS, Dang G, Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A. 1997;94:6658–63.PubMedPubMed CentralView ArticleGoogle Scholar
  29. Yao Y, Wang H, Li B. LDH5 overexpression is associated with poor survival in patients with solid tumors: a meta-analysis. Tumour Biol. 2014;35:6973–81.PubMedView ArticleGoogle Scholar
  30. Granchi C, Bertini S, Macchia M, Minutolo F. Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem. 2010;17:672–97.PubMedView ArticleGoogle Scholar
  31. Gao P, Tchernyshyov I, Chang T, Lee Y, Kita K, Ochi T, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–5.PubMedPubMed CentralView ArticleGoogle Scholar
  32. Miranda-Goncalves V, Honavar M, Pinheiro C, Martinho O, Pires MM, Pinheiro C, et al. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets. Neuro Oncol. 2013;15:172–88.PubMedPubMed CentralView ArticleGoogle Scholar
  33. Baltazar F, Pinheiro C, Morais-Santos F, Azevedo-Silva J, Queiros O, Preto A, et al. Monocarboxylate transporters as targets and mediators in cancer therapy response. Histol Histopathol. 2014;29:1511–24.PubMedGoogle Scholar
  34. Newsholme E, Crabtree B, Ardawi M. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep. 1985;5:393–400.PubMedView ArticleGoogle Scholar
  35. DeBerardinis R, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci U S A. 2007;104:19345–50.PubMedPubMed CentralView ArticleGoogle Scholar
  36. Wise D, DeBerardinis R, Mancuso A, Sayed N, Zhang X, Pfeiffer H, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci U S A. 2008;105:18782–7.PubMedPubMed CentralView ArticleGoogle Scholar
  37. Kim S, Yoo Y, Lee J, Park J. Mitochondrial NADP(+)-dependent isocitrate dehydrogenase knockdown inhibits tumorigenicity of melanoma cells. Biochem Biophys Res Commun. 2014;451:246–51.PubMedView ArticleGoogle Scholar
  38. Reitman Z, Duncan C, Poteet E, Winters A, Yan L, Gooden D, et al. Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia. J Biol Chem. 2014;289:23318–28.PubMedPubMed CentralView ArticleGoogle Scholar
  39. Losman J, Kaelin WJ. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836–52.PubMedPubMed CentralView ArticleGoogle Scholar
  40. Saha S, Parachoniak C, Ghanta K, Fitamant J, Ross K, Najem M, et al. Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513:110–4.PubMedPubMed CentralView ArticleGoogle Scholar
  41. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, et al. Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science. 2013;340:622–6.PubMedView ArticleGoogle Scholar
  42. Emadi A, Jun S, Tsukamoto T, Fathi A, Minden M, Dang C. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014;42:247–51.PubMedView ArticleGoogle Scholar
  43. Seltzer M, Bennett B, Joshi A, Gao P, Thomas A, Ferraris D, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010;70:8981–7.PubMedPubMed CentralView ArticleGoogle Scholar
  44. Gross A, McDonnell J, Korsmeyer S. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899–911.PubMedView ArticleGoogle Scholar
  45. Czabotar P, Lessene G, Strasser A, Adams J. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15:49–63.PubMedView ArticleGoogle Scholar
  46. Reed J, Zha H, Aime-Sempe C, Takayama S, Wang H. Structure-function analysis of Bcl-2 family proteins. Regulators of programmed cell death. Adv Exp Med Biol. 1996;406:99–112.PubMedView ArticleGoogle Scholar
  47. Kelekar A, Thompson C. Bcl-2-family proteins: the role of the BH3 domain in apoptosis. Trends Cell Biol. 1998;8:324–30.PubMedView ArticleGoogle Scholar
  48. Tait S, Green D. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621–32.PubMedView ArticleGoogle Scholar
  49. Zimmermann K, Bonzon C, Green D. The machinery of programmed cell death. Pharmacol Ther. 2001;92:57–70.PubMedView ArticleGoogle Scholar
  50. Lomonosova E, Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene. 2008;27 Suppl 1:S2–19.PubMedPubMed CentralView ArticleGoogle Scholar
  51. Ni Chonghaile T, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene. 2008;27 Suppl 1:S149–57.PubMedView ArticleGoogle Scholar
  52. Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–81.PubMedView ArticleGoogle Scholar
  53. Lessene G, Czabotar P, Colman P. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008;7:989–1000.PubMedView ArticleGoogle Scholar
  54. Danial N, Gramm C, Scorrano L, Zhang C, Krauss S, Ranger A, et al. BAD and glucokinase reside in a mitochondrial complex that integrates glycolysis and apoptosis. Nature. 2003;424:952–6.PubMedView ArticleGoogle Scholar
  55. Winter P, Sarosiek K, Lin K, Meggendorfer M, Schnittger S, Letai A, et al. RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis. Sci Signal. 2014;7:ra122.PubMedPubMed CentralView ArticleGoogle Scholar
  56. Sastry K, Al-Muftah M, Li P, Al-Kowari M, Wang E, Ismail Chouchane A, et al. Targeting proapoptotic protein BAD inhibits survival and self-renewal of cancer stem cells. Cell Death Differ. 2014;21:1936–49.PubMedPubMed CentralView ArticleGoogle Scholar
  57. Chang C, Shen C, Su H, Chen C. Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation. J Neurooncol. 2011;105:507–22.PubMedView ArticleGoogle Scholar
  58. Lowman X, McDonnell M, Kosloske A, Odumade O, Jenness C, Karim C, et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. Mol Cell. 2010;40:823–33.PubMedView ArticleGoogle Scholar
  59. Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24:499–511.PubMedView ArticleGoogle Scholar
  60. Lin H, Chen M, Chiu C, Song Y, Lin S. Cdk5 regulates STAT3 activation and cell proliferation in medullary thyroid carcinoma cells. J Biol Chem. 2007;282:2776–84.PubMedView ArticleGoogle Scholar

Copyright

© Li et al. 2016

Advertisement